T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product

Journal of Immunology

Volumn 172, Issue 10, 2004, Pages 6057-6064

  Huang, Jianping ^a   El Gamil, Mona ^a   Dudley, Mark E ^a   Li, Yong F ^a   Rosenberg, Steven A ^a   Robbins, Paul F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; GENE PRODUCT; HLA A11 ANTIGEN; HLA ANTIGEN CLASS 1; PROTEIN P14ARF; PROTEIN P16; PROTEIN P16INK4A; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ADULT; ARTICLE; CASE REPORT; CELL TRANSFER; CONTROLLED STUDY; DNA LIBRARY; EPITOPE MAPPING; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE ISOLATION; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; MELANOMA; METASTASIS; MULTIPLE REGRESSION; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE;

EID: 2442467847     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.10.6057     Document Type: Article

References (33)

1. Robbins, P. P., R.-F. Wang, and S. A. Rosenberg. 2000. Tumor antigens recognized by cytotoxic lymphocytes. In Cytotoxic Cells: Basic Mechanisms and Medical Applications. M. V. Sitkovsky and P. A. Henkart, eds. Lippincott Williams & Wilkins, Philadelphia, p. 363.
2. Ikeda, H., B. Lethe, F. Lehmann, N. van Baren, J. F. Baurain, C. de Smet, H. Chambost, M. Vitale, A. Moretta, T. Boon, and P. G. Coulie. 1997. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199.
3. Hanada, K., D. M. Perry-Lalley, G. A. Ohnmacht, M. P. Bettinotti, and J. C. Yang. 2001. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res. 61:5511.
4. Wolfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wolfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K. H. Meyer zum Buschenfelde, and D. Beach. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281.
5. Mandruzzato, S., F. Brasseur, G. Andry, T. Boon, and P. van der Bruggen. 1997. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186:785.
6. Brandle, D., F. Brasseur, P. Weynants, T. Boon, and B. Van den Eynde. 1996. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183:2501.
7. + T cells. J. Exp. Med. 189:1659.
8. Saeterdal, I., S. Bjorheim, K. Lislerud, M. K. Gjertsen, I. K. Bukholm, O. C. Olsen, J. M. Nesland, J. A. Eriksen, M. Moller, A. Lindblom, and G. Gaudernack. 2001. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc. Natl. Acad. Sci. USA 98:I3255.
9. Rubinfeld, B., P. Robbins, M. El-Gamil, I. Albert, E. Porfiri, and P. Polakis. 1997. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 275:1790.
10. Linard, B., S. Bezieau, H. Benlalam, N. Labarriere, Y. Guilloux, E. Diez and F. Jotereau. 2002. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J. Immunol. 168:4802.
11. Quelle, D. E., F. Zindy, R. A. Ashmun, and C. J. Sherr. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993.
12. Serrano, M., G. J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704.
13. Kamijo, T., J. D. Weber, G. Zambetti, F. Zindy, M. F. Roussel, and C. J. Sherr. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95:8292.
14. Ruas, M., and G. Peters. 1998. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta 1378:F115.
15. Foulkes, W. D., T. Y. Flanders, P. M. Pollock, and N. K. Hayward. 1997. The CDKN2A (p16) gene and human cancer. Mol. Med. 3:5.
16. Papp, T., H. Schipper, H. Pemsel, R. Bastrop, K. M. Muller, T. Wiethege, D. G. Weiss, E. Dopp, D. Schiffmann, and Q. Rahman. 2001. Mutational analysis of N-ras, p53, p16INK4a, p14ARF, and CDK4 genes in primary human malignant mesotheliomas. Int. J. Oncol. 18:425.
17. Sun, S., P. M. Pollock, L. Liu, S. Karimi, S. Jothy, B. J. Milner, A. Renwick, N. J. Lassam, N. K. Hayward, D. Hogg, et al. 1997. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int. J. Cancer 73:531.
18. Dudley, M. E., J. Wunderlich, M. I. Nishimura, D. Yu, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, R. Sherry, et al. 2001. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24:363.
19. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038.
20. Bettinotti, M. P., L. Hadzikadic, E. Ruppe, G. Dhillon, D. S. Stroncek, and F. M. Marincola. 2003. New HLA-A, -B, and -C locus-specific primers for PCR amplification from cDNA: application in clinical immunology. J. Immunol. Methods 279:143.
21. Naviaux, R. K., E. Costanzi, M. Haas, and I. M. Verma. 1996. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J. Virol. 70:5701.
22. Lapointe, R., R. E. Royal, M. E. Reeves, I. Altomare, P. F. Robbins, and P. Hwu. 2001. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class H epitopes from the melanoma antigen glycoprotein 100. J. Immunol. 167:4758.
23. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850.
24. Cairns, P., T. J. Polascik, Y. Eby, K. Toldno, J. Califano, A. Merlo, L. Mao, J. Herath, R. Jenkins, W. Westra, et al. 1995. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet. 11:210.
25. Cheng, J. Q., S. C. Jhanwar, W. M. Klein, D. W. Bell, W. C. Lee, D. A. Altomare, T. Nobori, O. I. Olopade, A. J. Buckler, and J. R. Testa. 1994. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 54:5547.
26. Kawakami, Y., and S. A. Rosenberg. 1997. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int. Rev. Immunol. 14:173.
27. Robbins, P. F., M. El-Gamil, Y. F. Li, Y. Kawakami, D. Loftus, E. Appella, and S. A. Rosenberg. 1996. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183:1185.
28. Wang, R. F., M. R. Parkhurst, Y. Kawakami, P. F. Robbins, and S. A. Rosenberg. 1996. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183:1131.
29. Wang, R. F., S. L. Johnston, G. Zeng, S. L. Topalian, D. J. Schwartzentruber, and S. A. Rosenberg. 1998. A breast and melanoma-shared tumour antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 161:3598.
30. Obana, K., H. W. Yang, H. Y. Piao, T. Taki, K. Hashizume, R. Hanada, IC Yamamoto, Y. Tanaka, Y. Toyoda, J. Takita, et al. 2003. Aberrations of p16INK4A, p14ARF and p15Ink4B genes in pediatric solid tumours. Int. J. Oncol. 23:1151.
31. Zhang, Y., and Y. Xiong. 1999. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell 3:579.
32. Lilischkis, R., B. Sarcevic, C. Kennedy, A. Warlters, and R. L. Sutherland. 1996. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int. J. Cancer 66:249.
33. Hashemi, J., A. Platz, T. Ueno, U. Stierner, U. Ringborg, and J. Hansson. 2000. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res. 60:6864.